Skip to main content
. 2013 Jun;182(6):2071–2081. doi: 10.1016/j.ajpath.2013.02.029

Figure 6.

Figure 6

Anti–IL-17A treatment decreased VCAM-MPIO binding in CR-EAE mice on PSD 28. A–H: Images showing the interaction of VCAM-MPIO with VCAM-1 expressed on the endothelial surface detected as focal hypointensities on T2∗-weighted images. On PSD 28, in mice treated with anti–IL-17A, the presence of MPIO binding in the cortex/striatum (A), hippocampus/thalamus (B), midbrain (C), and cerebellum/medulla (D) was reduced compared with mice treated with IgG at the same level (E–H). I–L: Three-dimensional reconstruction showing that anti–IL17A–treated mice (I) exhibited less MPIO binding during remission (PSD 28) than IgG-treated mice (K). On PSD 42, no significant differences in MPIO binding were observed (J and L, respectively). M: A significant reduction in VCAM-MPIO binding in anti–IL-17A–treated animals (black bars) was found compared with IgG-treated controls (white bars) on PSD 28, but no significant difference was observed on PSD 42. Data are shown as means ± SEM. ∗P < 0.05. Dashed lines represented baseline VCAM-MPIO binding in naive animals.